Lynn M. Marcho

This study identifies Sertad4 as a fibroblast-specific regulator of cardiac fibrosis and remodeling, showing that its deletion reduces adverse outcomes after myocardial infarction.

The paper tests the in vivo efficacy of estrogen receptor β agonists combined with tamoxifen in endocrine-resistant breast cancer models, finding no tumor volume reduction despite in vitro success.